MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$156,691K
Proceeds from issuance of
common stock upon...
$23,374K
Proceeds from sale of
marketable securities
$3,384K
Net cash provided by
(used in) investing...
$90,892K
Net cash provided by
financing activities
$23,374K
Canceled cashflow
$69,183K
Revenue
$56,368K
Interest income
$5,876K
Income tax benefit
-$1,502K
Other segment items
-$53K
Net increase in
cash, cash...
$65,323K
Canceled cashflow
$48,943K
Purchase of marketable
securities
$68,968K
Purchases of property and
equipment
$215K
Stock-based compensation
$14,519K
Net income (loss)
$3,783K
Accounts payable
$3,003K
Non-cash lease expense
$439K
Depreciation
$407K
Canceled cashflow
$60,016K
Net cash (used in)
provided by operating...
-$48,943K
Canceled cashflow
$22,151K
Development department
expense (excluding...
$17,473K
Stock-based compensation
expense
$14,519K
Discovery department
expense (excluding...
$8,506K
Employee wages and
benefits - development
$5,952K
General and
administrative expenses...
$5,695K
Employee wages and
benefits - general and...
$4,723K
Employee wages and
benefits - discovery
$3,148K
Receivable from
collaboration partner
$53,542K
Accrued expenses and
other payables
-$10,792K
Deferred revenue
-$3,268K
Prepaid expenses and
other assets
$1,918K
Accretion of discount on
marketable securities
$1,025K
Operating lease liability
-$547K
Other
-$2K
Back
Back
Cash Flow
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)
source: myfinsight.com